Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	104.25	120.57	240.55	122.93	138.51	90.94
Short-Term Investments	9	29.72	0	0	1.47	0.74
Cash & Cash Equivalents	113.25	150.29	240.55	122.93	139.98	91.68
Cash Growth	-43.15%	-37.52%	95.69%	-12.18%	52.68%	26.07%
Receivables	3.51	3.8	6.35	2.63	1.65	0
Inventory	5.78	2.41	0.08	0	0	0
Other Current Assets	8.73	8.75	5.4	6.12	4.64	2.45
Total Current Assets	131.28	165.25	252.38	131.68	146.27	94.13
Property, Plant & Equipment	3.74	3.84	4.24	2.5	1.95	2.27
Other Long-Term Assets	2.34	1.82	2.9	2.66	2.25	2.44
Total Long-Term Assets	6.07	5.66	7.14	5.16	4.2	4.71
Total Assets	137.35	170.91	259.52	136.84	150.46	98.84
Accounts Payable	6.13	4	4.46	3.13	2.21	2.76
Deferred Revenue	17.73	17.55	16.29	0	0	0
Current Debt	17.91	13.76	1.02	0	0	0
Other Current Liabilities	0.99	5.31	3.25	37.44	8.52	5.27
Total Current Liabilities	42.76	40.62	25.02	40.57	10.73	8.03
Long-Term Debt	92.71	95.19	100.88	40.81	0	0
Other Long-Term Liabilities	18.31	18.33	17.63	1.98	2.53	3.04
Total Long-Term Liabilities	111.03	113.52	118.5	42.79	2.53	3.04
Total Liabilities	153.78	154.14	143.52	83.35	13.26	11.07
Total Debt	110.63	108.95	101.9	40.81	0	0
Debt Growth	6.67%	6.92%	149.69%	-	-	-
Retained Earnings	-610.6	-571.93	-430.52	-410.71	-311.93	-235.57
Comprehensive Income	0	-0.02	0	0	0	0
Shareholders' Equity	-16.43	16.77	116	53.49	137.2	59.57
Net Cash / Debt	2.63	41.34	138.66	82.12	139.98	91.68
Net Cash / Debt Growth	-97.25%	-70.19%	68.85%	-41.34%	52.68%	26.07%
Net Cash Per Share	0.05	0.77	3.55	2.24	5.13	6.73
Working Capital	88.52	124.62	227.36	91.11	135.54	86.1
Book Value Per Share	-0.29	0.31	2.97	1.46	5.03	4.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).